Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects

Mattila, Mauri J.; Patat, Alain; Seppαlä, Timo; Kalska, Hely; Jalava, Marja; Vanakoski, Jyrki; Lavanant, C.

doi:10.1007/s002280050178

Cited by 25 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amisulpride did not enhance alcohol induced cognitive impairment in healthy volunteers87 neither did it enhance the effects of sleep deprivation 88. Compared to haloperidol, again in volunteers, amisulpride did not disrupt cognitive skill learning on motor and executive tasks, like haloperidol there was cognitive slowing but to a much more minor degree 89.…”

Section: Amisulpride and Cognitionmentioning

confidence: 80%

Update on the management of symptoms in schizophrenia: focus on amisulpride

Mortimer¹

2009

NDT

View full text Add to dashboard Cite

Amisulpride is an atypical antipsychotic drug with a unique receptor pharmacology which is dose dependent. It is a standard treatment in dysthymia as well as in psychosis. Amisulpride is efficacious, effective and well tolerated in positive symptoms of schizophrenia: there is extensive evidence that it treats negative symptoms when given in low doses, although relative lack of EPS and an antidepressant effect may contribute. In first-episode patients amisulpride is an option, although there is little comparative work available. Amisulpride has the best evidence as an effective adjunct to clozapine treatment. Regarding intellectual function, amisulpride appears cognitive sparing but the clinical relevance of this remains obscure. There is evidence that amisulpride can improve social function but again there is little comparative work to demonstrate any particular advantages. Regarding the current conventional versus atypical antipsychotic controversy, amisulpride did better in switching studies and meta-analyses than in the single large pragmatic randomized trial reported to date. It is a versatile drug, and may offer advantages over other atypical antipsychotic drugs in the treatment of negative and depressive symptoms, and tolerability advantages such as the avoidance of weight gain. Essentially it rests with the treating clinician to employ a rational psychopharmacological approach towards the individual patient: there will be few circumstances in which amisulpride will not be a likely contender as a treatment choice.

show abstract

Section: Amisulpride and Cognitionmentioning

confidence: 80%

Update on the management of symptoms in schizophrenia: focus on amisulpride

Mortimer¹

2009

NDT

View full text Add to dashboard Cite

show abstract

“…In this context, the relative absence of motor impairment after amisulpride treatment has been related to its higher affinity for the D2/D3 receptors located on limbic and hippocampal structures [Bischoll, 1992;Mattila et al, 1996]. The increase in time spent in social investigation could reflect an anxiolytic action of amisulpride.…”

Section: Discussionmentioning

confidence: 97%

“…Although it is clinically more potent than sulpiride, their pharmacological profiles are very similar [Mattila et al, 1996]. Likewise, this compound acts as a dopamine receptor antagonist showing a similar affinity for D2 and D3 dopaminergic receptors, and no significant interaction with D1, D4, and D5 receptors has been described [Boyer et al, 1995;Schoemaker et al, 1997].…”

Section: Introductionmentioning

confidence: 95%

Behavioral profile of amisulpride in agonistic encounters between male mice

Manzaneque¹,

Navarro²

1999

Aggr. Behav.

View full text Add to dashboard Cite

Amisulpride is a substituted benzamide derivative that acts as a selective dopamine D2/ D3 receptor antagonist. Although the anti-aggressive properties of neuroleptic drugs are well known, the effects of amisulpride on agonistic interactions have not been explored, and there are no studies comparing acute and subchronic effects of this compound on aggression in rodents. In this study, we examined the action of amisulpride (5-25 mg/kg, i.p), administered acutely or subchronically for 10 days, on agonistic behavior elicited by isolation in male mice. Individually housed mice were exposed to anosmic "standard opponents" 30 min after drug administration, and the encounters were videotaped and evaluated using an ethologically based analysis. After acute treatment, amisulpride (5-20 mg/kg) exhibited an ethopharmacological profile characterized by a marked decrease of offensive behaviors (threat and attack) without an impairment of motor activity. By contrast, the anti-aggressive action of the highest dose used (25 mg/ kg) was accompanied by a weak increase of immobility. Body care was also significantly enhanced after treatment with the drug (20 and 25 mg/kg), emphasizing the involvement of dopaminergic receptors in this behavior. After subchronic treatment, no tolerance to amisulpride anti-aggressive activity was observed. Overall, this behavioral profile is similar to that observed by other atypical neuroleptics. Aggr. Behav. 25:225-232, 1999.

show abstract

“…Body sway This is an objective, sensitive, reliable and noninvasive method designed to assess the effects of drugs and alcohol on postural stability [44,45,[49][50][51][52].…”

Section: Pharmacodynamic Interactions Of Sodium Oxybate and Ethanolmentioning

confidence: 99%

“…The average root mean square i.e. the distance between the target and the position of the eye during the smooth pursuit was the main parameter.Body sway This is an objective, sensitive, reliable and noninvasive method designed to assess the effects of drugs and alcohol on postural stability [44,45,[49][50][51][52].Body sway was recorded using a force-platform (Win Posture®, Medicapteurs; Balma, France). Measurements of body sway (1 min with eyes open and 1 min with eyes closed) were recorded as recommended by the International Society of Posturography [53].…”

mentioning

confidence: 99%

Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers

Pross¹,

Patat²,

Vivet

et al. 2015

Brit J Clinical Pharma

View full text Add to dashboard Cite

AIMThe pharmacologic effects of sodium oxybate (SO) have a number of similarities with those of alcohol. This study evaluated the pharmacodynamic interaction of SMO.IR (a solid immediate release formulation of SO) and alcohol (0.7 (males) or 0.57 (females) g kg -1 alcohol using 40% vodka). METHODSIn a randomized, double-blind, double-dummy, crossover trial, 24 healthy volunteers received randomly a) 2.25 g SMO.IR and placebo alcohol preparation, b) 2.25 g f SMO.IR and alcohol, c) 2.25 g SMO.IR matching placebo and alcohol and d) 2.25 g of SMO.IR matching placebo and placebo alcohol preparation. Objective and subjective cognitive parameters, adverse events and vital signs were assessed before, 15 and 165 min after treatment administration. RESULTSAlcohol produced the expected cognitive impairment and the expected subjective sedation rapidly after intake (from 15 min). The objective effects of SMO.IR were much less pronounced than those of alcohol. The reverse was observed for subjective complaints, which were related to lesser stimulation and greater sedation. Nevertheless, 165 min after administration this sedation feeling was less with SMO.IR than with alcohol. There was a significant interaction between SMO.IR and alcohol at 15 min (i.e. increase in alertness and stimulation and decrease in sedation). In addition, an isolated mild decrease in digit vigilance accuracy occurred at 165 min post-dose after the combination. The co-administration of SMO.IR and alcohol was safe and well-tolerated. CONCLUSIONSMO.IR and alcohol have distinct adverse effect profiles. The objective effects of SMO.IR are much less marked than those of alcohol. No deleterious interaction was observed. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Sodium oxybate (SO) has been approved for the treatment of alcohol dependence in Europe. Post-market surveillance has found no significant safety issues in alcohol relapsing patients taking SO, even though SO and alcohol share several pharmacological targets and effects.• Illicit SO (also called 'street GHB' or 'liquid ecstasy') can lead to abuse, misuse, addiction, criminal use and/or overdosing, and may have long term neurotoxic effects.• SMO.IR, a solid immediate-release formulation of sodium oxybate, is being developed to reduce the risk of criminal or accidental misuse of the drug and to obtain worldwide approval for the treatment of alcohol dependence. WHAT THIS STUDY ADDS• SMO.IR and alcohol have distinct adverse effect profiles. The objective sedative effects of SMO.IR are much less marked than those of alcohol and no interaction was observed.• The dose of SMO.IR used in this study (2.25 g) is in the upper range of the therapeutic interval for alcohol dependence and is 30%-80% higher than commonly prescribed doses.• The low level of interaction between alcohol and SMO.IR may account for the good safety profile of the drug even in the context of alcohol relapses. IntroductionSodium oxybate (SO) is the name of the sodium salt of gamma-hydroxybutyric acid when used as a therapeutic agent. Gamm...

show abstract

Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects

Abstract: Amisulpride in single oral doses of 50 and 200 mg did not interact significantly with the effects of high, moderate or low concentrations of ethanol on human skilled and cognitive performance. The drugs did interact pharmacokinetically.

Cited by 25 publications

References 15 publications

Update on the management of symptoms in schizophrenia: focus on amisulpride

Update on the management of symptoms in schizophrenia: focus on amisulpride

Behavioral profile of amisulpride in agonistic encounters between male mice

Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers

Contact Info

Product

Resources

About